

**COVID-19 Vaccine FAQ Sheet
(updated 1/25/2021)**

The AST has received queries from transplant professionals and the community regarding the COVID-19 vaccine. The following FAQ was developed to relay information on the current state of knowledge. This document is subject to change and will be updated frequently as new information or data becomes available.

What kinds of vaccines are available or under development to prevent COVID-19?

There are currently several vaccine candidates in use or under development. In the United States, the Government is supporting six separate vaccine candidates. Several other vaccines are also undergoing development outside of the United States government sponsorship and further information can be found here:

- **NYTimes Coronavirus Vaccine Tracker:**
<https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html>
- **Washington Post Vaccine Tracker:**
<https://www.washingtonpost.com/graphics/2020/health/covid-vaccine-update-coronavirus/>

The types of vaccines are as follows (January 25, 2021) ¹:

Table 1: Vaccines Under Development

Vaccine Type	Compound Name [Sponsor]	Clinical Trial Phase	Notes
mRNA	mRNA-1273 [Moderna]	Phase 3	Emergency use in U.S., E.U., other countries Approved in Canada
	BNT162b2 [Pfizer]	Phase 2/3	Emergency use in U.S., E.U., other countries Also approved in Canada and other countries
Replication-defective adenoviral vector	AZD1222 [AstraZeneca]	Phase 2/3	Emergency use in Britain, India, other countries (not U.S.)
	Ad26.COVS.2.S [Janssen]	Phase 3	

Recombinant-subunit-adjuvanted protein	NVX-CoV2373 [Novavax]	Phase 3	
	Recombinant SARS-CoV-2 Protein Antigen + AS03 Adjuvant [Sanofi Pasteur/GSK]	Phase 1/2	
Inactivated coronavirus	CoVaxin [Bharat Biotech]	Phase 3	Emergency Use in India
	BBIBP-CorV [Sinopharm]	Phase 3	Approved China, Bahrain, UAE; Emergency use elsewhere (not U.S.)

Both of the mRNA SARS-CoV-2 vaccines (Moderna, Pfizer) have been approved by Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) ². They have a 2-dose vaccination schedule and require cold storage.

When will these vaccines become available to transplant recipients?

Both the Pfizer and the Moderna vaccines are approved for Emergency Use Authorization (EUA) in the U.S. (Current: January 25, 2021).

The CDC Advisory Committee on Immunization Practices (ACIP) has proposed a phased distribution for the vaccine.^{3,4} Vaccine prioritization is driven by a balance of competing factors, including individual risk and community benefit. Older age, risk of SARS-CoV-2 exposure, and being an essential worker are considered important priorities. Most transplant recipients and candidates will fall under “people at high risk for severe COVID-19 due to underlying medical conditions.” ACIP notes that persons on immunosuppressive medications might be at increased risk for severe COVID-19 and that data are not available at this time to establish vaccine safety and efficacy in these individuals. They recommend that these people may receive COVID-19 vaccine along with counseling that there is unknown vaccine safety and efficacy profiles. In addition, there is a potential for reduced immune responses in those on immunosuppressive therapy.

States are allowed to define their own prioritization scheme which may affect how priority is determined; therefore, vaccine distribution may differ state by state. Although the exact timing and availability of vaccines are unknown, it is anticipated that transplant recipients may be included in groups for earlier vaccination.

Further updated information on vaccinations administered across the U.S. can be found here:

- **Bloomberg Vaccine Tracker:**
<https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/>

What is known about the safety of these vaccines?

The unprecedented speed of the vaccine development has been built upon prior research conducted in previous coronaviruses as well as vaccine approaches for other

novel viruses. Rigorous standards for safety were set forth by the FDA in June 2020, and all vaccine candidates must meet safety and effectiveness standards.

Although there are no licensed mRNA vaccines in the United States, they have been studied for decades for cancer and other infectious diseases. The safety profile of the mRNA SARS-CoV-2 vaccines administered to over 70,000 participants has not revealed any significant concerns at a median of 2 months follow up. At the time of this update, over 10 million doses have also been administered under the Emergency Use Authorization without additional concerns. The mRNA SARS-CoV-2 vaccines, similar to other common vaccines, are noted to cause fevers, muscle aches, and headaches; most are mild to moderate in severity, but some may be severe enough to briefly limit activities and typically resolve within 1-2 days. At this time, given the available data and that with other vaccines, the vast majority of serious side effects, if any, are noted in the first few days after vaccination, we do not expect that there will be significant side effects reported beyond the early post vaccination period.

The potential for anaphylaxis to either mRNA vaccine may range from 1/100,000 to 2.5/1,000,000; this is currently being closely monitored in the US and other countries. Patients who have known anaphylaxis to other vaccines should be counseled for the potential of a similar response and may be monitored up to 30 minutes after getting vaccinated. Skin and allergy testing are available in specialty centers to help differentiate individuals with high-level allergy. Those with allergies not related to vaccines, such as drug or food allergies should still receive the vaccine. At this time, it is recommended that all vaccine recipients should be monitored on site immediately following vaccination.

The safety of mRNA vaccines is still under investigation in solid organ transplant recipients. There were no transplant recipients in the phase 3 trials for Moderna or Pfizer, however, some transplanted individuals have already received vaccination as part of the Emergency Use Authorization. Based on their mechanism of action, expert opinion is that these vaccines are unlikely to trigger rejection episodes or have novel or more severe side effects in transplant recipients, but more data will be needed in.

The safety of other candidate vaccines will be updated as they get closer to emergency use authorization by updating this document.

How effective are these vaccines in transplant recipients?

The Pfizer and Moderna mRNA vaccines have data in immunocompetent people showing 94.1-95% efficacy in preventing infection COVID-19; vaccine efficacy appears similar in patients older than 65 years of age compared to younger patients. Data also suggest that when breakthrough infection occurs, disease is generally mild, showing the vaccines are also effective in preventing severe disease. Data regarding the durability of vaccine titers are still being gathered, although it currently appears that antibody titers persist for at least 4 months⁶.

The effectiveness of COVID-19 vaccines will need to be further studied in the solid organ transplant recipient. Solid organ transplant recipients may have generally lower antibody responses than those without transplants. Likewise, waning titers to other routine vaccines are well documented after transplantation. Lastly, patients vaccinated

pre-transplant, may have reduced protection post-transplant, particularly if therapies that reduce B-cell function (e.g. rituximab) are utilized.

When should a transplant recipient or candidate receive these vaccines?

The immunogenicity and efficacy of COVID-19 vaccines are unknown in transplant recipients. However, based on previous vaccination guidelines for solid organ transplant recipients, it is recommended that all transplant candidates and their household members receive vaccination when it becomes available. Ideally, transplant candidates should be targeted for vaccination while they are awaiting transplant. In general, vaccines are recommended more than 2 weeks prior to transplantation, or starting at 1-6 months after transplantation⁷. If given prior to transplant, ideally both doses should be completed before transplant, however, transplant deferral to complete the vaccine series should not be routinely done and needs to be decided on a case-by-case basis. In certain situations, it may be appropriate to wait until 3 months after transplantation to vaccinate, such as when T- or B-cell ablative therapy (anti-thymocyte globulin or rituximab) was used at time of transplant. If someone is transplanted after receipt of only 1 dose of vaccine, the optimal timing of the second dose is not defined. Expert opinion suggests waiting for at least 4 weeks to administer the second dose of vaccine, in order to allow time to decrease immunosuppression prior to second dose administration.

Can a transplant recipient still receive the vaccine even if they have had COVID-19?

The current guidance is that everyone receives the vaccine, irrespective of past COVID-19 infection or prior evidence of humoral immunity. There are case reports of immunosuppressed patients developing COVID-19 reinfection⁸, suggesting lack of appropriate immune response or waning immunity after the first infection. If a transplant recipient has had COVID-19, he/she should wait until all symptoms are resolved and the period of isolation has ended. The CDC currently recommends that vaccination should be postponed for 90 days following a more remote COVID-19 infection or following receipt of convalescent plasma or monoclonal antibody. The ideal period for vaccination after infection is still being investigated, however.

If a patient develops COVID-19 infection *after* the first dose of mRNA vaccination, but before the second dose, if possible, the second dose should be given once symptoms have resolved and the patient is outside the infectious window.

The impact of delaying the second dose on vaccine efficacy and durability has not been studied and should be avoided where possible. However, if a delay occurs because of incident COVID-19 infection, vaccine unavailability, or interval transplantation, delay should be kept as short as possible. Infectious diseases consultation is advisable in these situations.

Can patients stop wearing a mask after vaccination?

No. After vaccination, patients should be counseled to continue to practice COVID-19 safety measures including wearing masks around others, hand hygiene, and physical distancing in public places. It is likely that the efficacy and immunogenicity of vaccine in transplant recipients will be lower than shown in the vaccine clinical trials. In addition,

although vaccination substantially reduces the risk of symptomatic illness, it may not eliminate the risk of asymptomatic transmission of SARS-CoV-2.

Can the COVID-19 vaccines be given at the same time as other vaccines?

There are no data on safety or efficacy of the mRNA COVID-19 vaccines when administered with other vaccines. Therefore, the Advisory Committee on Immunization Practices recommends that the COVID-19 vaccine series should be administered alone and with a minimum of 14 days before or after giving any other vaccines.

Are there other things that transplant recipients need to consider about the vaccine?

Weighing the risks and benefits of getting vaccinated is important. While data are currently lacking specific to the vaccine in transplant recipients, it is reasonable to anticipate that vaccination will offer benefit. Likewise, transplant recipients appear to have clinically worse outcomes from SARS-CoV-2 infection compared to non-transplant recipients due to comorbidities or immunosuppression⁹. Thus, the benefits of vaccination outweigh any theoretical risks especially in countries where SARS-CoV-2 transmission continues at a high level. The transplant community is encouraged to collect data with regards to vaccination in order to inform future recommendations.

References

1. US Department of Health and Human Services (HHS). BARDA's Rapidly Expanding COVID-19 Medical Counter Measures. <https://www.medicalcountermeasures.gov/app/barda/coronavirus/COVID19.aspx?filter=vaccine>. Published 2020. Accessed December 21, 2020.
2. US Food and Drug Administration (FDA). COVID-19 Vaccines. <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines>. Published 2020. Accessed December 21, 2020.
3. Centers for Disease Control (CDC). Coronavirus Disease 2019 (COVID-19). <https://www.cdc.gov/coronavirus/2019-ncov/hcp/vaccination.html>. Published 2020. Accessed December 21, 2020.
4. Dooling K, McClung N, Chamberland M, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020. *MMWR Morb Mortal Wkly Rep*. ePub: 3 December 2020. DOI: <http://dx.doi.org/10.15585/mmwr.mm6949e1>. In.
5. Centers for Disease Control (CDC). Phased Allocation of COVID-19 Vaccines. In: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-12/slides-12-20/02-COVID-Dooling.pdf>. Published December 20, 2020. Accessed December 21, 2020.
6. Widge AT, Rouphael NG, Jackson LA, et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. *N Engl J Med*. 2020.
7. Danziger-Isakov L, Kumar D. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. *Clin Transplant*. 2019;33(9):e13563.
8. Tillett RL, Sevinsky JR, Hartley PD, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. *The Lancet Infectious Diseases*.
9. Caillard S, Chavarot N, Francois H, et al. Is Covid-19 infection more severe in kidney transplant recipients? *Am J Transplant*. 2020.